Topic: Biologics

How plan sponsors can contain rising drug costs in 2021

Staff | December 18, 2020 / News

A legislative update on provincial biosimilar policies

Kelsey Rolfe | December 18, 2020 / News

How are insurers using block-level contract amendments to control drug costs?

Kelsey Rolfe | September 28, 2020 / News

Mental-health conditions, specialty meds driving drug plan cost increases in 2019: report

Staff | July 9, 2020 / News

Drug plan considerations during the coronavirus pandemic

Kelsey Rolfe | April 20, 2020 / News

Proposed changes to Ontario drug rules target generics pricing, biosimilar listing process

Staff | November 14, 2019 / News

Switch from biologic to biosimilar drug requires monitoring, patient-informed discussion

Cassandra Williamson-Hopp | November 8, 2019 / News

How employers, health-care policies can support employees with irritable bowel disease

Cassandra Williamson-Hopp | October 18, 2019 / Health benefits

Policies around transitioning to biosimilars in Europe, the U.S. and Canada

Cassandra Williamson-Hopp | October 18, 2019 / News

Institutional investors urging Congress to vote down CUSMA, citing effect on drug prices

Kelsey Rolfe | September 23, 2019 / News